Merck (MRK)
NYSEMarket Open
Merck & Co., Inc. is a global pharmaceutical company that develops and sells prescription medicines, vaccines, biologic therapies, and animal health products. The company, known as MSD outside the United States and Canada, operates across major therapeutic areas including oncology, infectious disease, cardiometabolic disorders, immunology, and vaccines. Its scale, research base, and commercial reach make it one of the most important drugmakers in the global healthcare sector.
Merck’s largest growth driver is its oncology franchise, led by Keytruda, an immunotherapy used across multiple cancer types. Keytruda works by helping the immune system recognize and attack cancer cells, and it has become central to modern cancer treatment in many indications. Beyond oncology, Merck has a significant vaccines business, including products used in pediatric immunization and Gardasil, which helps protect against diseases caused by human papillomavirus.
The company also participates in infectious disease treatment and prevention, as well as selected areas of cardiometabolic care. In addition to human health, Merck operates an animal health division that supplies medicines, vaccines, and related products for livestock and companion animals, adding diversification beyond its core pharmaceutical portfolio.
Merck’s financial performance depends on patent protection, clinical trial success, regulatory approvals, pricing dynamics, and global healthcare demand. The United States is a major market for its human health products, but the company also sells extensively internationally. For investors, Merck represents exposure to a large research-driven pharmaceutical business with a leading cancer platform, a durable vaccines portfolio, and a meaningful presence in animal health.
Last updated
- Market Cap
- $366,004,912,497
- P/E
- 115.35
- P/FCF
- 22.79
- P/S
- 5.5
- Enterprise Value
- $413,061,912,497
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Address
- 126 EAST LINCOLN AVENUE, RAHWAY, NJ, 07065
SCHD Is Up Nearly 30% and Its Yield Is Back Near 3% | Did Dividend Investors Miss the Easy Money?
Merck (MRK) Stock Looks Fully Priced After A 127% Run
Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?
Merck Stock Hits New 52-Week High: What's Driving the Rally?
Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned.
Pfizer’s Turnaround is Gaining Traction, but Can New Products Offset its Patent Cliff?
Stocks making big moves this week: Bally's, Adobe, Novavax, Semtech, and STAAR Surgical
Moderna, Merck Cancer Vax Gives Hope
Merck (MRK) Gains A New Cancer Growth Story As Valuation Debate Heats Up
Thank Moderna for the Healthcare Sector’s Standout Week
Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech’s Biggest Players
Why Moderna’s mRNA Cancer Drug Hype Has Gone Too Far
Stocks making the biggest moves midday: Moderna, Robinhood, BJ's Wholesale, Coinbase & more
The Dow Jones Industrial Average buys its own bond problem
Merck's Near-Term Catalysts Create Bull-Bear Debate, RBC Capital Markets Says
Stock Market Rally Buckles; Moderna, Gold, Bitcoin Surge While Walmart Tumbles: Weekly Review
Pharma Stocks Have Rallied. 2 Stocks to Avoid—and 2 to Buy.
Big, bad bond market
Can Merck & Company (MRK)’s Stake in Evaxion A/S (EVAX) Validate the Potential of AI-Driven Vaccine Discovery?
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $366,004,912,497
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- $413,061,912,497
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 115.35
- P/B
P/B ratio compares a company's share price to its book value per share.
- 8.73
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 5.5
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 30.15
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 6.21
- EPS
- 1.29
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 2.27%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 22.79
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 18.33
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- $16,063,000,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 7.57%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 2.44%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 1.29
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.32
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.1
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.25
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $10,075,397
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 148.35
Income Statement
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Revenue | 16.61B | 16.29B | 16.4B | 17.28B | 15.81B |
| Cost of revenue | 4.4B | 4.2B | 5.55B | 3.86B | 3.56B |
| Gross profit | 12.21B | 12.09B | 10.85B | 13.42B | 12.25B |
| Operating income | -584M | -3.4B | 3.85B | 6.51B | 4.99B |
| EBITDA | 1.15B | -1.69B | 6.53B | 7.71B | 6.67B |
| Net income | -1.34B | -4.24B | 2.96B | 5.79B | 4.43B |
| Income taxes | 654M | 709M | 458M | 958M | 571M |
| Interest expense | -525M | 0 | 0 | 0 | -305M |
| Other operating expenses | 151M | 195M | 213M | 47M | 560M |
| Total operating expenses | 12.8B | 15.49B | 7B | 6.91B | 7.26B |
| Basic EPS | -0.54 | -1.72 | 1.19 | 2.32 | 1.76 |
| Diluted EPS | -0.54 | -1.72 | 1.19 | 2.32 | 1.76 |
Balance Sheet
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Total assets | 129.8B | 128.69B | 136.87B | 129.55B | 117.52B |
| Total liabilities | 87.82B | 82.75B | 84.2B | 77.64B | 68.46B |
| Total equity | 41.98B | 45.93B | 52.66B | 51.91B | 49.06B |
| Cash & equivalents | 6.85B | 5.33B | 14.57B | 18.17B | 8.01B |
| Current assets | 36.68B | 35.02B | 43.52B | 47.56B | 37.07B |
| Current liabilities | 27.73B | 26.95B | 28.33B | 28.63B | 26.04B |
| Accounts payable | 3.83B | 3.86B | 4.4B | 4.15B | 3.89B |
| Receivables | 12.56B | 12.21B | 11.78B | 12.12B | 11.85B |
| Inventories | 6.21B | 6.48B | 6.66B | 6.44B | 6.6B |
| Goodwill | 21.58B | 21.58B | 21.58B | 21.59B | 21.59B |
| Long-term debt | 51.08B | 46.67B | 46.75B | 39.97B | 33.97B |
Cash Flow
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Operating cash flow | 5.37B | 3.92B | 2.86B | 7.82B | 3.29B |
| Investing cash flow | -5.6B | -10.21B | -11.2B | -283M | -770M |
| Financing cash flow | 1.76B | -2.98B | 4.75B | 2.64B | -3.56B |
| Change in cash | 1.49B | -9.29B | -3.57B | 10.19B | -659M |
| Net income | -1.34B | -4.24B | 2.96B | 5.79B | 4.43B |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 144 — Merck & Co., Inc. | View Filing | |
| form 4 | Form 4 — Guindo Chirfi | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 144 — Merck & Co., Inc. | View Filing | |
| edgar index | 144 — Merck & Co., Inc. | View Filing | |
| form 4 | Form 4 — DeLuca Richard R. | View Filing | |
| form 4 | Form 4 — DeLuca Richard R. | View Filing | |
| form 4 | Form 4 — Zachary Jennifer | View Filing | |
| form 4 | Form 4 — Zachary Jennifer | View Filing | |
| form 4 | Form 4 — Zachary Jennifer | View Filing | |
| form 4 | Form 4 — Zachary Jennifer | View Filing | |
| form 4 | Form 4 — Zachary Jennifer | View Filing | |
| edgar index | 144 — Merck & Co., Inc. | View Filing | |
| form 4 | Form 4 — DeLuca Richard R. | View Filing | |
| form 4 | Form 4 — DeLuca Richard R. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 144 — Merck & Co., Inc. | View Filing | |
| form 4 | Form 4 — DeLuca Richard R. | View Filing | |
| edgar index | 13F-HR — Merck & Co., Inc. | View Filing | |
| edgar index | 10-Q — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 144 — Merck & Co., Inc. | View Filing | |
| edgar index | 144 — Merck & Co., Inc. | View Filing | |
| form 4 | Form 4 — Guindo Chirfi | View Filing | |
| form 4 | Form 4 — DeLuca Richard R. | View Filing | |
| form 4 | Form 4 — DeLuca Richard R. | View Filing | |
| form 4 | Form 4 — DeLuca Richard R. | View Filing | |
| edgar index | 144 — Merck & Co., Inc. | View Filing | |
| edgar index | 144 — Merck & Co., Inc. | View Filing | |
| form 4 | Form 4 — Williams David Michael | View Filing | |
| form 4 | Form 4 — Williams David Michael | View Filing | |
| form 4 | Form 4 — Williams David Michael | View Filing | |
| form 4 | Form 4 — Williams David Michael | View Filing | |
| form 4 | Form 4 — Williams David Michael | View Filing | |
| form 4 | Form 4 — Williams David Michael | View Filing | |
| form 4 | Form 4 — Williams David Michael | View Filing | |
| form 4 | Form 4 — Williams David Michael | View Filing | |
| form 4 | Form 4 — Williams David Michael | View Filing | |
| form 4 | Form 4 — Maraldo David R. | View Filing | |
| form 4 | Form 4 — Maraldo David R. | View Filing | |
| form 4 | Form 4 — Maraldo David R. | View Filing | |
| form 4 | Form 4 — Maraldo David R. | View Filing | |
| form 4 | Form 4 — Maraldo David R. | View Filing | |
| form 4 | Form 4 — Maraldo David R. | View Filing | |
| form 4 | Form 4 — Maraldo David R. | View Filing | |
| form 4 | Form 4 — Maraldo David R. | View Filing | |
| form 4 | Form 4 — Maraldo David R. | View Filing | |
| edgar index | 8-K — Merck & Co., Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| form 4 | Form 4 — Coe Mary Ellen | View Filing | |
| form 4 | Form 4 — Coe Mary Ellen | View Filing | |
| form 4 | Form 4 — Karsanbhai Surendralal Lanca | View Filing | |
| form 4 | Form 4 — Karsanbhai Surendralal Lanca | View Filing | |
| form 4 | Form 4 — Seidman Christine E | View Filing | |
| form 4 | Form 4 — Seidman Christine E | View Filing | |
| edgar index | 11-K — Merck & Co., Inc. | View Filing | |
| edgar index | 11-K — Merck & Co., Inc. | View Filing | |
| edgar index | 11-K — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing |